Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Non-randomized Trial to Investigate the Efficacy and Safety of Early Versus Delayed Start of Arimoclomol in Patients With Sporadic Inclusion Body Myositis Who Have Completed the IBM4809 Trial

NCT04049097 is registered in ClinicalTrials.gov with ZevraDenmark as lead sponsor.

NCT NCT04049097
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04049097 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Non-randomized Trial to Investigate the Efficacy and Safety of Early Versus Delayed Start of Arimoclomol in Patients With Sporadic Inclusion Body Myositis Who Have Completed the IBM4809 Trial
Lead sponsor
ZevraDenmark
Phase
Phase 3
Overall status
Terminated
Start date
May 20, 2019
Completion date
November 15, 2021
Enrollment
121 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

inclusion body myositis